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Acute pulmonary embolism (PE) is a leading cause of cardiovascular mortality. Systemic anticoagulation is the standard
of care, and treatment can be escalated in the setting of massive or submassive PE, given the high mortality risk. A
secondary consideration for intervention is the prevention of late-onset chronic thromboembolic pulmonary hyperten-
sion. Treatment options include systemic thrombolysis, catheter-directed interventions, and surgical thromboembolec-
tomy. Whereas systemic thrombolysis seems to be beneﬁcial in the setting of massive PE, it appears to be associated with a
higher rate of major complications compared with catheter-directed thrombolysis as shown in recent randomized trials
for submassive PE. The hemodynamic and clinical outcomes continue to be deﬁned to determine the indications for and
beneﬁts of intervention. The current review summarizes contemporary evidence on the role and outcomes of catheter-
directed therapies in the treatment of acute massive and submassive PE. (J Vasc Surg 2015;61:559-65.)Acute pulmonary embolism (PE) is the third leading THROMBOLYSIS FOR MASSIVE AND
cause of cardiovascular mortality, accounting for 5% to
10% of in-hospital deaths in the Western world.1 Recent
registries and cohort studies suggest that approximately
10% of all patients with diagnosed acute PE will die within
3 months after diagnosis.2,3 Management is mainly guided
by the acuity and severity of clinical presentation. Initial
systemic anticoagulation is the standard of care, and treat-
ment is escalated on the basis of the clinical presentation
and characteristics of patients that may stratify them at
high risk of mortality. Massive PE is deﬁned as PE associ-
ated with sustained hemodynamic instability, whereas sub-
massive PE is deﬁned as PE without hemodynamic
instability but with abnormal right ventricular (RV) func-
tion or evidence of myocardial necrosis.4 Treatment op-
tions include systemic thrombolysis, catheter-directed
interventions (CDIs) with or without local thrombolysis,
and surgical thromboembolectomy. The goals of therapy
are primarily to prevent mortality and secondarily to pre-
vent late-onset chronic thromboembolic pulmonary hyper-
tension and to improve quality of life. The current review
summarizes contemporary evidence emerging from recent
systematic reviews and randomized trials on the role and
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Systemic intravenous thrombolysis is universally rec-
ommended by all guideline bodies for massive PE but re-
mains controversial for submassive PE.4-7 The most
widely suggested regimen is 100 mg of alteplase during
2 hours.7
Massive PE. A meta-analysis of 11 historical (1973-
2002; n ¼ 748) randomized trials comparing heparin vs
heparin and thrombolysis in massive and submassive PE
showed no difference in PE recurrence and death.8 How-
ever, subgroup analysis for massive PE showed signiﬁcantly
better outcomes for thrombolysis vs heparin alone in com-
bined PE recurrence and death (19% vs 9.4%), accompanied,
though, by signiﬁcantly higher major bleeding rates (11.9%
vs 21.9%).8 A more recent analysis of a U.S. Nationwide
Inpatient Sample (1999-2008; n ¼ 72,230) demonstrated
an all-cause (47% vs 15%) and PE-related (42% vs 8.4%)
mortality beneﬁt for thrombolysis in massive PEs.9
Submassive PE. It is difﬁcult to demonstrate a survival
beneﬁt between either treatment (heparin vs heparin and
thrombolysis), given that mortality is infrequent in patients
with submassive PE. Quality of life measures such as late-
onset chronic thromboembolic pulmonary hypertension
and functional disability may be more relevant outcomes.
In the most recent meta-analysis of randomized controlled
trials comparing treatment alternatives, the subgroup
analysis of eight submassive PE trials (1993-2014; n ¼
1775) showed that thrombolytic therapy was associated
with a mortality reduction (1.39% vs 2.92%) and an in-
crease in major bleeding (7.74% vs 2.25%).10 These results
were mainly driven by the largest randomized trial (PEI-
THO; 1006 patients) that compared a single, weight-
adapted intravenous bolus of tenecteplase (not Food and
Drug Administration [FDA] approved) with standard
anticoagulation.11 PEITHO showed a signiﬁcant reduction559
Table. Summary of current evidence for catheter-directed interventions (CDIs)
Level of supporting studies Comments
Massive PE One systematic review (594 patients)19 Noncontrolled, nonhomogeneous studies including
various CDIs with and without lytics
Publication and selection bias
Survival 86.5% (range, 40%-100%)
Major complications 2.4%
One comparative study of USAT þ AC (15 patients)
vs CDI þ AC (18 patients)29
Small sample
Selection bias
No mortality difference
Fewer treatment-related complications for USAT
Prospective and retrospective case series of various
CDIs with and without lytics
No controls
Majority with <20 patients and selection bias
Submassive PE One randomized controlled trial comparing USAT þ
AC (30 patients) vs AC alone (29 patients)18
RV/LV ratio signiﬁcantly improved within 24 hours
in favor of USAT
No difference in RV/LV ratio improvement at
90 days [trend (P ¼ .07) in favor of USAT]
RV systolic function signiﬁcantly improved at both
24 hours and 90 days in favor of USAT
No major bleeding for either group
Systematic review of USAT (197 patients)20 18% had massive PE
RV/LV ratio decrease 24% within 24 hours
Relative reduction in the pulmonary occlusion score
32%-69%
Major bleeding 3.6%
No intracranial or fatal bleed
Unclear survival or long-term beneﬁts
Retrospective case series of various CDIs Majority with <20 patients and selection bias
Areas of uncertainty or areas in need of higher quality evidence
Anticoagulation vs CDI in massive PE with contraindications to systemic lysis
Low-dose systemic lysis protocols vs CDIs in massive and submassive PE
Risk stratiﬁcation and selection of patients with submassive PE who would beneﬁt from CDIs
Long-term outcomes (pulmonary hypertension and quality of life) after CDI in submassive PE
AC, Anticoagulation; PE, pulmonary embolism; RV/LV, right ventricle/left ventricle; USAT, ultrasound-assisted thrombolysis.
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and hemodynamic decompensation at 7 days in favor of
tenecteplase (5.6% vs 2.6%). The main driver for the efﬁ-
cacy difference, however, was not mortality but a reduction
in hemodynamic collapse. The beneﬁts of thrombolysis
came at the cost of a signiﬁcant risk increase of extracranial
major bleeding complications (1.2% vs 6.3%) and hemor-
rhagic stroke (0.2% vs 2.0%), particularly evident in the
elderly (>75 years old).11 Of note, only 3.4% of patients in
the anticoagulation group had clinical deterioration that
required thrombolysis, suggesting that a strategy of anti-
coagulation with thrombolysis reserved for patients who do
not respond to standard therapy may be acceptable, partic-
ularly for older patients.11 Five smaller randomized trials
have investigated the efﬁcacy and side effects of low-dose
alteplase (50 mg) in predominantly submassive PE, and a
recent meta-analysis (1990-2013; 440 patients) suggested
that it has similar efﬁcacy but is safer than the standard
100-mg dose. In addition, compared with heparin, low-dose
protocols do not increase the risk of major bleeding com-
plications for eligible PE patients.12 As for later onset pul-
monary hypertension, there is some recent evidence from
three small randomized studies and a prospective uncon-
trolled trial that pulmonary artery pressures rise in the
majority of patients with submassive PE but decline in thosewho are treated with thrombolysis, potentially altering
exercise tolerance and quality of life.7,13-16
CDI
Despite the lack of sufﬁcient direct evidence through
controlled studies (CDIs vs anticoagulation or vs high- or
low-dose systemic lysis), the beneﬁcial effects, the limita-
tions, and the anticipated complications of systemic
thrombolysis in both massive and submassive PE drive
contemporary practice toward CDIs as a ﬁrst-line treat-
ment in the appropriate clinical setting17-20 (Table).
Massive PE
A systematic review of 35 noncontrolled studies (1998-
2008; 594 patients) reporting on various CDIs for massive
PE showed a pooled survival rate of 86.5% (range, 40%-
100%).19 In 95% of these patients, CDIs were initiated
without prior intravenous thrombolysis, and only 60% to
67% received a thrombolytic agent. The success was higher
in studies in which at least 80% of participants received local
thrombolytic therapy during the procedure (91.2% vs
82.8%). Pooled risks of minor and major procedural com-
plications were 7.9% and 2.4%, respectively. Twenty-ﬁve
major complications were reported and included bleeding
complications requiring transfusion, renal failure requiring
Fig 1. Suggested algorithm for the management of acute pulmonary embolism (PE). RV, Right ventricle; SBP, systolic
blood pressure. *Hypokinesis on echocardiography or elevated troponin I or Twith local thresholds (values exceeding the
99th percentile with coefﬁcient of variability<10%) or brain natriuretic peptide>90 pg mL1 or amino-terminal pro-B-
type natriuretic peptide>900 pgmL1. zAbsolute contraindications: any prior intracranial hemorrhage; known structural
intracranial cerebrovascular disease or neoplasm; ischemic stroke within 3 months; suspected aortic dissection; active
bleeding or bleeding diathesis; recent spinal or cranial/brain surgery; recent closed head or facial trauma with bone
fracture or brain injury. Relative contraindications: age $75 years; current use of anticoagulation; pregnancy;
noncompressible vascular punctures; traumatic or prolonged cardiopulmonary resuscitation; recent internal bleeding (2-
4 weeks); history of chronic, severe, and poorly controlled hypertension; severe uncontrolled hypertension on presen-
tation; dementia; remote (3 months) ischemic stroke; major surgery within 3 weeks.
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events, and death.19
Submassive PE
The ﬁrst randomized controlled trial to include CDIs
for submassive PE was recently published.18 The Ultra-
sound Accelerated Thrombolysis of Pulmonary Embolism
(ULTIMA) trial compared standardized ﬁxed-dose ultra-
sound-assisted catheter-directed thrombolysis (USAT)
(10 mg of recombinant tissue-type plasminogen activator
per lung during 15 hours) and anticoagulation with antico-
agulation alone. The primary outcome was reversal of RV
dilation in intermediate-risk PE patients (2010-2013; 59
patients). In the USAT group but not in the heparin
group, the mean right ventricle/left ventricle ratio was
signiﬁcantly reduced at 24 hours but became comparable
between the two groups at 90 days, with a trend in favor
of USAT (P ¼ .07). The RV systolic function was signiﬁ-
cantly improved in the USAT group vs the heparin group
at both 24 hours and 90 days. The ULTIMA trial was
not designed to show long-term superiority of USAT to
anticoagulation alone, however, nor was it powered toshow any difference in survival. In both study groups,
bleeding complications were rare, with three (10%) minor
bleedings in the interventional group and one (3%) in the
control group. There were no major bleeding complica-
tions. At 90 days, there were no episodes of hemodynamic
decompensation or recurrent PE in any group.18
A systematic review including seven USAT studies
(2008-2013; 197 patients; 18% massive PE) followed the
publication of the ULTIMA trial, reinforcing its ﬁndings.20
Notably, these studies primarily included patients with in-
termediate risk or submassive PE; thus, it remains unclear
if USAT acts fast enough to prevent hemodynamic deteri-
oration and death in unstable patients with massive PE.
However, the proven beneﬁt of CDI in this population
of patients had been established in the aforementioned sys-
tematic review on non-USAT catheter techniques for
massive PE.19
There is no clinical trial comparing CDIs with systemic
thrombolysis for PE and no randomized controlled trial
comparing CDIs vs anticoagulation alone speciﬁcally for
massive PE. However, in light of all the recently published
data, mainly the PEITHO and the ULTIMA trials for
Fig 2. A 60-year-old otherwise healthy man presented with severe chest tightness, dyspnea, and near-syncope.
Computed tomography angiography showed saddle pulmonary embolism (PE) with a large thrombus burden in the
main segmental branches (R > L). He had worsening respiratory function and right-sided heart strain but no he-
modynamic decompensation. Catheter-directed thrombolysis was performed. a, Pulmonary angiogram showing
bilateral segmental thrombus (arrows). b, EKOS catheters were placed within the thrombus, and a lytic infusion was
initiated (the arrows indicate the multiside hole infusion segments of the catheters and the inner wire segments with
ultrasound microtransducers). c, Lysis check at 16 hours showed thrombus resolution, along with decreased oxygen
requirements and normalization of right ventricular function.
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necessarily improve mortality rates, can improve RV func-
tion, and may prevent hemodynamic decompensation.
They are also associated with a better safety proﬁle, with
decreased complication rates compared with systemic
thrombolysis, shifting the harm-beneﬁt ratio in favor of
CDI. Whenever thrombolysis is considered beneﬁcial in
the setting of massive PE and in selected cases of submas-
sive PE, CDI is the only alternative for patients at higher
bleeding risk and can be considered a reasonable alternative
in patients at low risk for bleeding, provided there is local
expertise and around-the-clock availability. In addition,
catheter techniques should be considered an escalation ther-
apy when systemic thrombolysis has failed.21 Given the lack
of deﬁned treatment algorithms and clear superiority of one
therapy over the other, individualized patient decisions are
best made as part of a multidisciplinary discussion among
the different members of a PE team (Fig 1).
Technical considerations
Contemporary CDIs are variable and can be performed
with or without thrombolysis. The latter include thrombus
fragmentation or aspiration techniques, with no lytic agents,
for patients with absolute contraindications to thromboly-
sis; their efﬁcacy, however, remains controversial.7,19,20
The standard technique involves administration of
local thrombolytics through a multiside hole catheter
placed unilaterally or bilaterally into the pulmonary artery
thrombus. Several adjuncts and technical alternatives
have been described in various combinations, targeting
rapid clot debulking. The majority of these technical ad-
juncts and devices lack background evidence and are not
approved by the U.S. FDA for treatment of PE. As such,
no standardized technical algorithm yet exists.
A clinically relevant reduction in thrombus burden
rather than complete thrombus removal guides therapy.
Invasive pressure tracings (right atrium, right ventricle,
main pulmonary artery) before and after each treatmentsession or cardiac echocardiographic parameters can be
used as adjuncts to monitor the progress of therapy. In
massive PE, reversal of hemodynamic instability should pri-
marily guide the termination of treatment. In patients with
massive PE that was “downstaged” to submassive, or in
submassive PE, continuation of catheter-directed throm-
bolysis should be guided by improved pulmonary artery
pressures and reversal of right-sided heart strain, barring
any complications that necessitate discontinuation of ther-
apy or surgical conversion.19,22,23
Thrombus fragmentation. Rotating pigtail catheter
fragmentation has been widely reported and used22; it is
easily available and comes at a low cost. As it leads to distal
clot embolization, adjunctive aspiration thrombectomy
may be needed. Unless the thrombus is fragmented to
allow a greater embolic surface area to the lytic drug’s ef-
fect, thrombolytic infusion into the pulmonary artery
proximal to the embolus will be no more efﬁcacious than
systemic delivery as it tends to rapidly wash into non-
occluded arteries.19,22,24,25
The AngioJet Rheolytic Thrombectomy System (Bayer
HealthCare, Medrad Inc, Indianola, Pa) provides pharma-
comechanical thrombolysis and has been used in the past
for PE, with several adverse events reported. Despite a
recent study advocating its use in the setting of massive
PE, it should probably by avoided.19,22,26-28
The use of ultrasound to enhance thrombolytic perme-
ation of large emboli holds currently the highest level of ev-
idence in both efﬁcacy and safety (see previous section).18,20
However, the clinical superiority of ultrasound-assisted
thrombolysis over conventional catheter-directed throm-
bolysis has not been proved.29 The EkoSonic Endovascular
System (EKOS Corporation, Bothell, Wash) combines a
multieside hole drug infusion catheter with a multielement
ultrasound core wire and was recently approved by the FDA
for use in patients with PE (Fig 2).
Thrombus aspiration. Thrombus aspiration can be per-
formed either as an adjunct to any CDI or as a stand-alone
Fig 3. Massive pulmonary embolism (PE; right ventricular strain and hemodynamic decompensation) in a patient with
recent surgery and with intrapulmonary bleed due to the pulmonary infarct. a, Intraoperative pulmonary angiogram
indicating bilateral thrombus (arrows) (L > R). b, Pigtail rotation within the major clot burden. c, Aspiration
thrombectomy with a 10F Pronto catheter (Vascular Solutions, Minneapolis, Minn). d, Extracted thromboembolic
material.
Fig 4. Submassive pulmonary embolism (PE; right ventricular strain without hemodynamic decompensation) with
increasing oxygen requirement, in a young patient, after brain abscess evacuation. a, Pulmonary angiogram showing
bilateral thrombus (R > L) (the arrow points to the occluded right main pulmonary artery). b, AngioVac (Angio-
Dynamics, Latham, NY) aspiration from a jugular approach. c, Extracted thromboembolic material. Cardiopulmonary
parameters subsequently normalized.
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simplest aspiration technique is by using any 5F to 9F
end-hole catheter or dedicated steerable aspiration cath-
eters 10F to 14F in size22,30 (Fig 3).
A novel device but with limited evidence in the PE
setting is the Vortex AngioVac aspiration system (Angio-
Dynamics, Latham, NY), which is composed of an extra-
corporeal bypass circuit that facilitates drainage, ﬁltration,
and reinfusion of blood cleared from clot.31 A funnel-
shaped distal tip facilitates en bloc removal of the embolus.
The technique is FDA approved, and successful outcomes
in the setting of PE have been reported in small case series.
The device requires a 26F delivery sheath and can be used
from the femoral or jugular approach and allows embolec-
tomy without the use of lytic agents (Fig 4).
CONCLUSIONS
There is increasing evidence that percutaneous CDIs
are an essential, effective, and safe alternative to systemic
thrombolysis or anticoagulation in the contemporary man-
agement of massive and submassive PE. Robust,
adequately powered studies comparing systemic vs
catheter-directed thrombolysis for massive and submassive
PE as well as different catheter-based techniques are still
needed to determine the effect on survival, bleeding com-
plications, and quality of life outcomes.
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